By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Agios Pharmaceuticals 

38 Sidney Street
2nd Floor
Cambridge  Massachusetts  02139-4169  U.S.A.
Phone: 617-649-8600 Fax: n/a


Company News
Agios Pharmaceuticals (AGIO) Announces That Celgene (CELG) Has Agreed To Exercise Its Option To License AG-120 Under Global Strategic Collaboration 1/13/2015 6:57:53 AM
Agios Pharmaceuticals (AGIO) To Present At The 33rd Annual J.P. Morgan Healthcare Conference On Monday, January 12 1/6/2015 8:47:06 AM
Agios Pharmaceuticals (AGIO) Announces Closing Of Public Offering And Full Exercise Of Over-Allotment Option 12/17/2014 7:39:09 AM
Agios Pharmaceuticals (AGIO) Announces Pricing Of $220 Million Public Offering Of Common Stock 12/11/2014 7:30:29 AM
Agios Pharmaceuticals (AGIO) Announces Proposed Offering Of Common Stock 12/10/2014 6:57:44 AM
Agios Pharmaceuticals (AGIO) Appoints Kaye Foster-Cheek To Its Board Of Directors 12/10/2014 6:56:50 AM
Agios Pharmaceuticals (AGIO) Reports Positive Phase 1 Data In Healthy Volunteers For AG-348, A First-In-Class Investigational Medicine That Targets The Underlying Cause Of Pyruvate Kinase (PK) Deficiency 12/9/2014 10:17:24 AM
Agios Pharmaceuticals (AGIO) Announces Celgene (CELG) Decision To Extend Discovery Phase Of Global Strategic Collaboration To April 2016 12/8/2014 8:34:12 AM
Agios Pharmaceuticals (AGIO) Announces New Data From Ongoing Phase 1 Trial Of AG-221 Showing Robust Clinical Activity In Patients With Advanced Hematologic Malignancies 12/8/2014 7:31:58 AM
Agios Pharmaceuticals (AGIO) Announces Early Phase 1 Data Showing Clinical Activity Of AG-120 As A Single Agent In Advanced Acute Myeloid Leukemia (AML) 11/18/2014 4:43:48 PM